Healthcare provider profile · identity verified

Robin Frances Dore, PA-C

Physician Assistant · PLANO, TX · NPI 1114208824

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	277	100
Atorvastatin Calcium	Atorvastatin Calcium	183	61
Rosuvastatin Calcium	Rosuvastatin Calcium	175	58
Alprazolam	Alprazolam	173	44
Amlodipine Besylate	Amlodipine Besylate	138	51
Lisinopril	Lisinopril	114	44
Gabapentin	Gabapentin	113	39
Albuterol Sulfate Hfa	Albuterol Sulfate	96	35
Metformin Hcl	Metformin Hcl	95	33
Losartan Potassium	Losartan Potassium	94	34
Tramadol Hcl	Tramadol Hcl	94	26
Pantoprazole Sodium	Pantoprazole Sodium	93	32
Hydrochlorothiazide	Hydrochlorothiazide	82	26
Trazodone Hcl	Trazodone Hcl	78	30
Azithromycin	Azithromycin	75	58
Metoprolol Succinate	Metoprolol Succinate	72	25
Meloxicam	Meloxicam	70	25
Omeprazole	Omeprazole	70	27
Clonazepam	Clonazepam	69	15
Ozempic	Semaglutide	67	14
Zolpidem Tartrate	Zolpidem Tartrate	67	22
Testosterone Cypionate	Testosterone Cypionate	65	19
Liothyronine Sodium	Liothyronine Sodium	64	20
Tamsulosin Hcl	Tamsulosin Hcl	63	29
Montelukast Sodium	Montelukast Sodium	62	20
Escitalopram Oxalate	Escitalopram Oxalate	56	20
Simvastatin	Simvastatin	55	19
Clopidogrel	Clopidogrel Bisulfate	51	16
Estradiol	Estradiol	51	21
Sertraline Hcl	Sertraline Hcl	51	13
Mounjaro	Tirzepatide	46	suppressed
Tizanidine Hcl	Tizanidine Hcl	46	suppressed
Duloxetine Hcl	Duloxetine Hcl	43	12
Metoprolol Tartrate	Metoprolol Tartrate	42	20
Celecoxib	Celecoxib	41	suppressed
Furosemide	Furosemide	39	16
Valsartan	Valsartan	39	15
Pioglitazone Hcl	Pioglitazone Hcl	38	15
Prednisone	Prednisone	38	21
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	37	30
Methylprednisolone	Methylprednisolone	37	29
Acetaminophen-Codeine	Acetaminophen With Codeine	36	11
Methocarbamol	Methocarbamol	35	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	34	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	33	21
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Lorazepam	Lorazepam	32	suppressed
Pregabalin	Pregabalin	31	suppressed
Potassium Chloride	Potassium Chloride	30	suppressed
Carvedilol	Carvedilol	29	13
Fluconazole	Fluconazole	29	18
Glimepiride	Glimepiride	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	11
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Jardiance	Empagliflozin	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	14
Buspirone Hcl	Buspirone Hcl	26	11
Synthroid	Levothyroxine Sodium	26	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Eliquis	Apixaban	24	suppressed
Ondansetron Odt	Ondansetron	24	11
Progesterone	Progesterone, Micronized	24	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Diazepam	Diazepam	23	suppressed
Dutasteride	Dutasteride	23	suppressed
Armour Thyroid	Thyroid,pork	21	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Eszopiclone	Eszopiclone	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Tresiba Flextouch U-100	Insulin Degludec	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Metronidazole	Metronidazole	18	suppressed
Mupirocin	Mupirocin	18	13
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	16
Modafinil	Modafinil	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Temazepam	Temazepam	15	suppressed
Terbinafine Hcl	Terbinafine Hcl	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Fluticasone Propionate	Fluticasone Propionate	14	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	11
Trulicity	Dulaglutide	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Cefdinir	Cefdinir	13	13
Ezetimibe	Ezetimibe	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Estradiol (Once Weekly)	Estradiol	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Nystatin	Nystatin	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error